Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | PLA2G4B | P0C869 | 7/20 | 0.65 |
| ▸ | RARB | P10826 | 4/20 | 0.61 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26089107 | 1.00 | TSHR (0.67) | TSHRTP53HTTPLA2G4BRARB | |
| SCHEMBL9329263 | 1.00 | TSHR (0.67) | TSHRTP53HTTPLA2G4BRARB | |
| SCHEMBL4211416 | 0.98 | TSHR (0.64) | TSHRTP53HTTPLA2G4BRARB | |
| SCHEMBL4275826 | 0.90 | HDAC1 (0.56) | TSHRHTTGAAHSD17B10 | |
| SCHEMBL28706802 | 0.88 | GAA (0.75) | TSHRTP53HTTPLA2G4BGAA | |
| SCHEMBL28693964 | 0.88 | GAA (0.75) | TSHRTP53HTTPLA2G4BGAA | |
| SCHEMBL28706034 | 0.88 | GAA (0.75) | TSHRTP53HTTPLA2G4BGAA | |
| SCHEMBL4262672 | 0.88 | MAPT (0.70) | TSHRTP53HTTTDP1GAA | |
| SCHEMBL2603390 | 0.86 | L3MBTL1 (0.74) | HTTPOLBGAA | |
| SCHEMBL5187570 | 0.86 | MAPT (0.72) | HTTTDP1GAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2024-10-24 | — | — | US | disclosed |
| EP-4313991-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-117295747-A | Anti-cancer nuclear hormone receptor targeting compounds | 诺维逊生物股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20220340587-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-10-27 | — | — | US | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022204184-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| US-8563741-B2 | CDK inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-10-22 | — | — | US | disclosed |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009036016-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240352027-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | TSHR 115/4885TP53 55/4885HTT 3436/4885 |
| US-20220340587-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | TSHR 115/4885TP53 55/4885HTT 3436/4885 |
| US-20090093507-A1 | CDK INHIBITORS CONTAINING A ZINC BINDING MOIETY | CDK3, CDKL1, CDKL3 | TSHR 3508/4885TP53 252/4885HTT 3759/4885 |
| US-11834458-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | TSHR 115/4885TP53 55/4885HTT 3436/4885 |
| US-20260116890-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR3C1, NCOR1 | TSHR 52/4885TP53 81/4885HTT 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.